![]() |
||||||||||||||||||||||||||||||||||||||||||||
![]() |
TolnaftateClass: Thiocarbamates Antifungal; thiocarbamate.a Uses for Tolnaftate DermatophytosesTreatment of tinea corporis (body ringworm)109 and tinea cruris (jock itch)110 111 caused by Epidermophyton floccosum, Microsporum canis, M. audouinii, Trichophyton mentagrophytes, T. rubrum, or T. tonsurans.109 110 111 a Treatment of tinea pedis (athlete’s foot) and tinea manuum† (hand ringworm) caused by E. floccosum, M. canis, M. audouinii, T. mentagrophytes, T. rubrum, or T. tonsurans.109 110 111 a Available for self-medication (OTC use) for treatment of tinea corporis,109 tinea cruris,110 111 or tinea pedis and for prevention of reinfection of tinea pedis.109 110 111 Should not be used for treatment of dermatophyte infections that occur on scalp or nails.109 110 111 Topical antifungals usually effective for treatment of uncomplicated tinea corporis and tinea cruris.100 101 104 105 106 An oral antifungal may be necessary when tinea corporis or tinea cruris is extensive, dermatophyte folliculitis is present, infection is chronic or does not respond to topical therapy, or patient is immunocompromised because of coexisting disease or concomitant therapy.100 101 104 105 106 Topical antifungals usually effective for treatment of uncomplicated tinea pedis.100 101 104 105 106 An oral antifungal may be necessary for treatment of hyperkeratotic areas on palms and soles,101 106 for chronic moccasin-type tinea pedis,100 101 105 and for treatment of tinea unguium (fingernail or toenail dermatophyte infections, onychomycosis).100 101 104 105 106 Pityriasis (Tinea) VersicolorTreatment of pityriasis (tinea) versicolor† caused by Malassezia furfur (Pityrosporum orbiculare or P. ovale).100 Topical antifungals generally effective;100 102 103 105 107 an oral antifungal (with or without a topical antifungal) may be necessary in patients who have extensive or severe infections or have failed to respond to or have frequent relapses with topical therapy.102 103 105 Tolnaftate Dosage and Administration Administration Topical AdministrationApply topically to the infected skin as a 1% cream, aerosol liquid spray, aerosol powder spray, powder, or solution.109 110 111 a Avoid contact with eyes, nose, mouth, and other mucous membranes.109 110 111 a Do not apply to scalp or nail infections.109 110 111 Clean affected areas with soap and water and dry thoroughly prior to applying preparation.109 110 111 a A small amount of the cream or powder or 2 or 3 drops of the solution should be rubbed gently into affected areas.109 110 111 a Alternatively, a thin layer of aerosol liquid spray or aerosol spray powder should be applied.111 a Although pruritus, burning, and soreness may be relieved within 24–72 hours after initiation of therapy, complete the full course of treatment.a When treating tinea pedis, pay special attention to spaces between toes.109 111 Also, wear well-fitting, ventilated shoes and change shoes and socks at least once daily.109 111 Dosage Pediatric Patients Dermatophytoses Tinea Corporis or Tinea Cruris TopicalChildren ?2 years of age: Apply to affected area twice daily (morning and night) for 4 weeks for tinea corporis109 or 2 weeks for tinea cruris.110 If improvement does not occur after 4 weeks of treatment, diagnosis and therapy should be reevaluated.109 110 a Tinea Pedis TopicalChildren ?2 years of age: Apply to affected area twice daily (morning and night) for 4 weeks.109 110 111 If improvement does not occur after 4 weeks of treatment, diagnosis and therapy should be reevaluated.109 110 111 a Daily use after treatment may help prevent reinfection.109 110 111 Pityriasis (Tinea) Versicolor† TopicalChildren ?2 years of age: Apply to affected area twice daily (morning and night).100 a If improvement does not occur after 4 weeks of treatment, diagnosis and therapy should be reevaluated.a Adults Dermatophytoses Tinea Corporis or Tinea Cruris TopicalApply to affected area twice daily (morning and night) for 4 weeks for tinea corporis109 or 2 weeks for tinea cruris.110 If improvement does not occur after 4 weeks of treatment, diagnosis and therapy should be reevaluated.109 110 a Tinea Pedis TopicalApply to affected area twice daily (morning and night) for 4 weeks.109 110 111 If improvement does not occur after 4 weeks of treatment, diagnosis and therapy should be reevaluated.109 110 111 a Daily use after treatment may help prevent reinfection.109 110 111 Pityriasis (Tinea) Versicolor† TopicalApply to affected area twice daily (morning and night).100 a If improvement does not occur after 4 weeks of treatment, diagnosis and therapy should be reevaluated.a Cautions for Tolnaftate ContraindicationsKnown hypersensitivity to tolnaftate or any ingredient in the formulation.a Warnings/Precautions Warnings Administration PrecautionsFor external use only.109 110 111 Do not administer orally or intravaginally.a Avoid contact with nose, mouth, and other mucous membranes.109 110 111 a Do not apply to eye.109 110 111 a If contact with the eye(s) occurs, wash with large amounts of water; consult a clinician if ocular irritation persists.a Intentional misuse by deliberately concentrating and inhaling the contents of the aerosols can be harmful or fatal.111 Sensitivity ReactionsIf irritation or hypersensitivity occurs, discontinue drug and consult clinician.109 110 111 a Sensitization to butylated hydroxytoluene, which is present in some creams, solutions, and aerosol powder formulations, has been confirmed.a Specific Populations PregnancyCategory C.112 LactationSafety not established.112 Pediatric UseShould not be used in children <2 years of age unless otherwise directed by a clinician.109 110 111 Common Adverse EffectsSkin irritation.a Interactions for TolnaftateNo formal drug interaction studies to date.a Stability Storage Topical Cream20–25°C.109 Avoid freezing.a Powder and SolutionStore in tight containers at <40°C, preferably between 15–30°C.a Avoid freezing.a Aerosol2–30°C.a Do not use near fire or flame; do not expose to temperatures >49°C.111 a Actions and SpectrumActionsThiocarbamate antifungal structurally and pharmacologically unrelated to other commercially available antifungals.a May be fungistatic or fungicidal against susceptible organisms.a Mechanism of antifungal activity unknown.a Appears to distort the hyphae and stunt mycelial growth in susceptible fungi.a Dermatophytes: Active in vitro against Epidermophyton floccosum, Microsporum audouinii, M. canis, M. gypseum, M. japonicum, Trichophyton mentagrophytes, T. rubrum, T. schoenleinii, and T. tonsurans.a Inactive against Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus.a Inactive against bacteria, protozoa, and viruses.a Advice to PatientsImportance of applying to affected areas as directed and avoiding contact with eyes, nose, mouth, or other mucous membranes.109 110 111 Importance of completing full course of treatment, even if symptoms improve.109 110 111 a Importance of contacting clinician if improvement does not occur by end of prescribed treatment period.109 110 111 a Importance of consulting clinician if treated area becomes irritated, blisters, swells, or oozes.109 110 111 a Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs.109 110 111 a Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.109 110 111 a Importance of informing patients of other important precautionary information.109 110 111 a (See Cautions.) PreparationsExcipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. * available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name TolnaftateRoutes Dosage Forms Strengths Brand Names Manufacturer Topical Aerosol 1% Tinactin Liquid Aerosol (with SD alcohol 40-2 36% w/w) Schering-Plough Ting Antifungal Spray Insight Aerosol Powder 1% Tinactin Jock Itch Spray Powder (with SD alcohol 40-2 14% w/w) Schering-Plough Tinactin Powder Aerosol (with SD alcohol 40-2 14% w/w) Schering-Plough Cream 1%* Tinactin (with propylene glycol) Schering-Plough Tinactin Jock Itch Cream (with propylene glycol) Schering-Plough Ting Antifungal Cream Insight Powder 1%* Tinactin Schering-Plough Solution 1%* Tinactin Schering-Plough DisclaimerThis report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use. The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care. AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions August 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814. † Use is not currently included in the labeling approved by the US Food and Drug Administration. References100. Gupta AK, Einarson TR, Summerbell RC et al. An overview of topical antifungal therapy in dermatomycoses: a North American perspective. Drugs. 1998; 55:645-74. [PubMed 9585862] 101. Pi?rard GE, Arrese JE, Pi?rard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs. 1996; 52:209-24. [PubMed 8841739] 102. Sunenshine PJ, Schwartz RA, Janniger CK. Tinea versicolor: an update. Cutis. 1998; 61:65-72. [PubMed 9515210] 103. Assaf RR, Weil ML. The superficial mycoses. Dermatol Clin. 1996; 14:57-67. [PubMed 8821158] 104. Lesher JL. Recent developments in antifungal therapy. Dermatol Clin. 1996; 14:163-9. [PubMed 8821170] 105. Hay RJ. Dermatophytosis and other superficial mycoses. In: Mandel GL, Douglas RG Jr, Bennett JE, eds. Principles and practices of infectious disease. 4th ed. New York: Churchill Livingston; 1995: 2375-86. 106. Drake LA, Dincehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. J Am Acad Dermatol. 1996; 34:282-6. [IDIS 363962] [PubMed 8642094] 107. Drake LA, Dinehart SM, Farmer ER et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. J Am Acad Dermatol. 1996; 34:287-9. [IDIS 363963] [PubMed 8642095] 108. Reviewers’ comments (personal observations) on Sulconazole 84:04.08. 109. Schering-Plough HealthCare Products. Tinactin (tolnaftate) cream 1% prescribing information. Memphis, TN. Undated. 110. Insight Pharmaceuticals. Ting (tolnaftate) cream 1% prescribing information. Langhorne, PA. 2006. 111. Insight Pharmaceuticals. Ting (tolnaftate) spray liquid 1% prescribing information. Langhorne, PA. 2006. 112. Robertson J, Shilkofski N, eds. The Harriet Lane handbook: a manual for pediatric house officers. 17th ed. Philadelphia, PA: Elsevier Mosby: 2005:987. a. AHFS drug information 2007. McEvoy GK, ed. Tolnaftate. Bethesda, MD: American Society of Health-System Pharmacists; 2007:3394. More Tolnaftate resources Tolnaftate Side Effects (in more detail)Tolnaftate Use in Pregnancy & BreastfeedingTolnaftate Support Group1 Review for Tolnaftate - Add your own review/rating Absorbine Athletes Foot Concise Consumer Information (Cerner Multum) Absorbine Jr. Antifungal Topical Advanced Consumer (Micromedex) - Includes Dosage Information Blis-To-Sol Powder MedFacts Consumer Leaflet (Wolters Kluwer) Desenex Spray MedFacts Consumer Leaflet (Wolters Kluwer) Tinactin Cream MedFacts Consumer Leaflet (Wolters Kluwer) Compare Tolnaftate with other medications Tinea CorporisTinea CrurisTinea PedisTinea Versicolor |
![]() |
|
|||||||||||||||||||||||||||||||||||||||||
Site Map | PageMap Copyright © RX Pharmacy Drugs List. All rights reserved. |